Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of GATOR1 complex protein NPRL2 including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into GATOR1 complex protein NPRL2 therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of GATOR1 complex protein NPRL2, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on GATOR1 complex protein NPRL2. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of GATOR1 complex protein NPRL2. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for GATOR1 complex protein NPRL2 includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
GATOR1 complex protein NPRL2
partner:
Reaxense
upacc:
Q8WTW4
UPID:
NPRL2_HUMAN
Alternative names:
Gene 21 protein; Nitrogen permease regulator 2-like protein; Tumor suppressor candidate 4
Alternative UPACC:
Q8WTW4; A8K831; Q6FGS2; Q9Y249; Q9Y497
Background:
The GATOR1 complex protein NPRL2, also known as Gene 21 protein, Nitrogen permease regulator 2-like protein, and Tumor suppressor candidate 4, plays a pivotal role in cellular metabolism. It acts as the catalytic component of the GATOR1 complex, inhibiting the mTORC1 pathway in response to amino acid depletion. This regulation is crucial for cellular growth and response to nutrient availability.
Therapeutic significance:
NPRL2's involvement in familial focal epilepsy with variable foci 2 highlights its potential as a target for therapeutic intervention. Its ability to suppress cell growth and enhance sensitivity to anticancer drugs further underscores its significance in developing treatments for epilepsy and cancer.